Newcastle Magnetic Resonance Centre

Projects

A Phase III, Multicentre, randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Efficacy and Safety Study of Crenezumab in patients with prodromal to mild alzheimers disease (CREAD)

Staff Profile: Dr Robert Barber